Literature DB >> 3632139

Evidence for a class 4 effect of cibenzoline "in vivo".

A Sassine, C Massé, J Brugada, L C Romero-Ayala, M Canovas, M Cazes, P Puech.   

Abstract

In anesthetized dogs, it has already been shown that cibenzoline (4 mg/kg i.v.) possesses class 1 anti-arrhythmic properties. In this work, the cardiac electrophysiologic effects of cibenzoline (1 mg/kg i.v.) were studied before and after propranolol (0.2 mg/kg i.v.) treatment. Cibenzoline caused a slight tachycardia, a reduction of conduction velocity in the His-Purkinje system and in the ventricle, but no significant effects in the atria and the atrioventricular node were detected. On the contrary, when dogs were given the beta-adrenoceptor blocking agent propranolol, cibenzoline produced major effects in the slow response structures, especially in the sinus node and the atrioventricular node (bradycardia and depression of the atrioventricular nodal conduction). No further effects were observed on the His-Purkinje system and ventricle as compared to administration of cibenzoline alone. In dogs, cibenzoline given i.v., had no effects on the slow response systems, probably because of sympathetic nervous system intervention since the class 4 effects of cibenzoline appeared after beta-adrenoceptor blockade.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3632139

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  2 in total

1.  Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers.

Authors:  Mihoko Kawabata; Yasuhiro Yokoyama; Takeshi Sasaki; Susumu Tao; Kensuke Ihara; Yasuhiro Shirai; Tetsuo Sasano; Masahiko Goya; Tetsushi Furukawa; Mitsuaki Isobe; Kenzo Hirao
Journal:  Clin Pharmacol       Date:  2015-02-16

2.  Genome-driven elucidation of phage-host interplay and impact of phage resistance evolution on bacterial fitness.

Authors:  Pawel Markwitz; Cédric Lood; Tomasz Olszak; Vera van Noort; Rob Lavigne; Zuzanna Drulis-Kawa
Journal:  ISME J       Date:  2021-08-31       Impact factor: 10.302

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.